Previous 10 | Next 10 |
– Biopharmaceutical Industry Veteran Brings Expertise in Global Drug Development and Corporate Governance – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid int...
Dicerna Pharmaceuticals (DRNA) is a clinical stage biotechnology company specializing in RNAi-based medicines. Its most advanced candidate is nedosiran for primary hyperoxaluria, a rare genetic disease. But it also has entered into collaboration agreements with Boehringer Ingelheim, Alexion ( ...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will be participating in three virtual investor conferences in September: Citi’s 15 th Annual BioPharma Con...
Dicerna Pharmaceuticals, Inc. (DRNA) Q2 2020 Earnings Conference Call August 6, 2020 10:00 AM ET Company Participants Doug Fambrough - President and Chief Executive Officer Bob Brown - Chief Scientific Officer and Executive Vice President, R&D Man-Fung Yuen - Chair Professor,...
The following slide deck was published by Dicerna Pharmaceuticals, Inc. in conjunction with this Read more ...
Dicerna Pharmaceuticals ( DRNA -6.1% ) has shared interim Phase 1 data on its Roche-partnered hepatitis B drug RG6346, demonstrating reduced hepatitis B surface antigen (HBsAg). More news on: Dicerna Pharmaceuticals, Inc., Healthcare stocks news Read more ...
Dicerna Pharmaceuticals (NASDAQ: DRNA ) : Q2 GAAP EPS of -$0.43 misses by $0.53 . More news on: Dicerna Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
– In the Ongoing Phase 1 Proof-of-Concept Trial Multidose Group, RG6346 1.5, 3.0 and 6.0 mg/kg Dosing Cohorts Reached Mean HBsAg Reduction From Baseline of 1.39, 1.80 and 1.84 Log10 IU/mL, Respectively, at Day 112 End-of-Treatment; Data for Earliest-Dose Cohort of 1.5 mg/kg Showed Du...
– Company Targeting Enrollment Completion for Pivotal PHYOX™2 Trial of Nedosiran in Fourth Quarter 2020 – – Company Reported $669.2 Million in Cash, Cash Equivalents and Marketable Securities as of June 30, 2020 – – Management to Host Virt...
– Dr. Aradhye Brings to Dicerna More Than 20 Years of Successfully Leading Global Teams in Developing Diverse Portfolios of Innovative Medicines – Dicerna Pharmaceuticals, Inc . (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer ...
News, Short Squeeze, Breakout and More Instantly...
Dicerna Pharmaceuticals Inc. Company Name:
DRNA Stock Symbol:
NASDAQ Market:
Dicerna Pharmaceuticals Inc. Website:
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstan...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Easter...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...